Quantcast

Latest non-Hodgkin's lymphoma Stories

2014-06-09 12:26:41

Public Healthcare Systems in Brazil and Mexico Cover Targeted Therapies but with Indication-Specific Restrictions, According to Findings from Decision Resources Group BURLINGTON, Mass., June 9, 2014 /PRNewswire/ -- Decision Resources Group finds that targeted therapies such as MabThera (rituximab) for non-Hodgkin's lymphoma (NHL) and Velcade (bortezomib) for multiple myeloma (MM) enjoy extensive but incomplete coverage in Brazil and Mexico through complex mechanisms. To obtain reimbursement,...

2014-05-31 08:21:05

- Data include results from two Phase I studies of ABT-199/GDC-0199 in relapsed/refractory chronic lymphocytic leukemia (CLL) and various subtypes of non-Hodgkin's lymphoma (NHL) NORTH CHICAGO, Ill., May 31, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) released interim results from a Phase Ib clinical trial of ABT-199/GDC-0199, an investigational B-cell lymphoma 2 (BCL-2) selective inhibitor, in combination with rituximab (Abstract 7013). Results showed an overall response rate (ORR) of...

2014-03-22 23:02:28

Researchers say a drug approved for the treatment of relapsed T-cell Non-Hodgkin’s Lymphoma may help people with indolent B-cell varieties, too. Raleigh, NC (PRWEB) March 22, 2014 Scientists studying the Non-Hodgkin’s Lymphoma drug Zolinza (vorinostat) say it may improve outcomes for patients fighting indolent B-cell lymphomas like follicular lymphoma and mantle cell lymphoma. The Phase II study, published in the British Journal of Haematology and reported by the Non-Hodgkin’s...

2014-03-19 23:26:27

A new study indicates that an investigational drug for relapsed Non-Hodgkin’s Lymphoma called pixantrone (Pixuvri) is safer for the heart than the current front-line treatment. Raleigh, NC (PRWEB) March 19, 2014 Research published in Reproductive Toxicology and reported by the Non-Hodgkin’s Lymphoma Center suggests that there may be a better treatment option for people with relapsed or refractory (recurrent) aggressive Non-Hodgkin’s Lymphoma. Non-Hodgkin’s Lymphoma patients who...

2014-03-17 23:23:11

Scientists say patients with certain forms of aggressive Non-Hodgkin’s Lymphoma are more likely to survive if they respond well to their first treatment. Raleigh, NC (PRWEB) March 17, 2014 An article published in the journal Cancer and reported by the Non-Hodgkin’s Lymphoma Center sheds new light on the prognosis for patients with certain forms of Non-Hodgkin’s Lymphoma. Doctors with the James Comprehensive Cancer Center at Ohio State University focused on two specific subtypes of...

2014-03-15 23:01:54

NIH researchers say risks from occupational exposures such as PCBs cannot be ruled out. Raleigh, NC (PRWEB) March 15, 2014 Researchers with the National Institute of Occupational Safety and Health in Cincinnati find that men who work with microelectronics and business machines may be more likely to die of cancer, including Non-Hodgkin’s Lymphoma. A new study published in the American Journal of Industrial Medicine and reported by the Non-Hodgkin’s Lymphoma Center focused on 34,494...

2014-03-12 23:24:38

Researchers say a combination of bendamustine and rituximab may be just as effective and less toxic than standard chemotherapy for indolent lymphomas. Raleigh, NC (PRWEB) March 12, 2014 According to the Non-Hodgkin’s Lymphoma Center, a study published in the journal Blood suggests that patients with certain kinds of Non-Hodgkin’s Lymphomas may get equally good results from a new chemotherapy combination than from the standard drugs. Researchers at the Sarah Cannon Research Institute...

2014-03-10 23:24:25

Targeted drug aims to address high recurrence and lower survival in people with B-cell cancers. Raleigh, NC (PRWEB) March 10, 2014 The Non-Hodgkin’s Lymphoma Center is reporting on new published research on an experimental Non-Hodgkin’s Lymphoma drug that appears to boost the power of existing medications. SNS01-T is a mixture of nanoparticles designed to interfere with the inner workings of malignant B-cells in patients with Non-Hodgkin’s Lymphoma and other B-cell cancers. A new...

2014-03-09 23:01:39

Two new studies in major medical journals may help doctors understand how Non-Hodgkin’s Lymphoma starts, and predict treatment outcomes. Raleigh, NC (PRWEB) March 09, 2014 The Non-Hodgkin’s Lymphoma Center is reporting on new research suggesting that overweight Non-Hodgkin’s Lymphoma patients are just as likely to respond well to treatment as patients with lower BMIs. The report, published in the Annals of Oncology, is one of two new Non-Hodgkin’s Lymphoma risk studies....

2014-03-07 23:21:39

A new article in a top medical journal says appropriate use of a safer chemotherapy drug could open up more treatment options for Non-Hodgkin’s Lymphoma patients. Raleigh, NC (PRWEB) March 07, 2014 The Non-Hodgkin’s Lymphoma Center is reporting on a new article published in Leukemia & Lymphoma journal suggesting that an alternative to a popular Non-Hodgkin’s Lymphoma drug can reduce the risk of heart problems and help more patients. This is especially good news for elderly...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related